For example, the results of KEYNOTE-012 and KEYNOTE-028 indicated that pembrolizumab, a type of anti-PD-1 antibody, may be a promising agent in pretreated and PD-L1-positive advanced GC. Here, CD274 is linked to gastric cancer.